AnaptysBio, Inc. (ANAB) Tops Q3 EPS by 56c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall, dragged by Alphabet and megacap tech; focus on Iran
- Oil falls almost 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
AnaptysBio (ANAB) PT Lowered to $52 at H.C. Wainwright
November 6, 2024 6:12 AM ESTH.C. Wainwright analyst Emily Bodnar lowered the price target on AnaptysBio (NASDAQ: ANAB) to $52.00 (from $55.00) while maintaining a Buy rating.
The analyst comments "3Q24 financial recap; lowering PT to $52 from $55. AnaptysBio had 3Q24 total operating expenses of $52.8M, which were slightly... More
AnaptysBio (ANAB) PT Lowered to $45 at Leerink Partners
November 6, 2024 5:58 AM ESTLeerink Partners analyst David Risinger lowered the price target on AnaptysBio (NASDAQ: ANAB) to $45.00 (from $47.00) while maintaining a Outperform rating.
The analyst comments " Bottom Line: ANAB reported 3Q results and stated that there have been no blinded safety issues to date with either its BTLA... More
